A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder"

Administered By

Awarded By

Contributors

Start/End

  • June 23, 2017 - June 12, 2020